Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Thomas Olencki"'
Autor:
Elizabeth A. Streacker, Thomas Olencki, Volodymyr Karpa, Kala M. Levine, William E. Carson, Lorena P. Suarez-Kelly, Joseph Markowitz, Sara E. Martin del Campo, Taylor R. Brooks, Kari Kendra, Anissa Bingman, Susan Geyer
Publikováno v:
Cancer Immunology, Immunotherapy
Melanoma is a highly immunogenic tumor and consequently, efforts have been centered on the development of immune-based treatments for this malignancy [1]. Interferons were initially described in the mid-1950s as proteins that interfere with viral rep
Publikováno v:
Current Problems in Cancer. 46:100805
Patient survival with renal cell carcinoma (RCC) has improved with the use of molecular targeted agents and immunotherapy. Given the potential activity of these agents in treating brain metastases, the role of aggressive local management with surgery
Publikováno v:
Neuro Oncol
INTRO Programmed cell death protein 1 (PD1)-inhibitor, nivolumab, and cytotoxic T-lymphocyte-associated protein 4 (CTLA4)-inhibitor, ipilimumab, have been shown to be efficacious in treatment of metastatic renal cell carcinoma (RCC). Clinical trials
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50286aa9065f99e75618791a737dd9ec
https://europepmc.org/articles/PMC6847417/
https://europepmc.org/articles/PMC6847417/
Autor:
Karin G. Hoffmann, Manisha J. Loss, Roy H. Decker, Rachel C. Blitzblau, Sumaira Z. Aasi, Murad Alam, Karthik Ghosh, Yaohui G. Xu, Roy C. Grekin, Valencia Thomas, Ashok R. Shaha, Anita M. Engh, James S. Andersen, Kishwer S. Nehal, Thomas Olencki, Carlo M. Contreras, Kenneth Grossman, Glen M. Bowen, Gregory A. Daniels, Kris Fisher, Alan L. Ho, Jane L. Messina, Paul Nghiem, John A. Zic, Igor Puzanov, Karl D. Lewis, Daniel D. Lydiatt, Brian R. Gastman, Jeffrey M. Farma, Chrysalyne D. Schmults, Christopher K. Bichakjian
Publikováno v:
J Natl Compr Canc Netw
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiati
Autor:
David F. McDermott, Thomas Olencki, Ulka N. Vaishampayan, Mariajose Lechuga, Saby George, Kathrine C. Fernandez, Jamal Tarazi, Daniel C. Cho, Brad Rosbrook, Igor Puzanov, Toni K. Choueiri, Elizabeth R. Plimack, Mayer Fishman, Michael B. Atkins
Publikováno v:
The Lancet Oncology. 19:405-415
Summary Background Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity, precluding further development. We hypothesised that axitinib, a more selective V
Autor:
John Y.S. Kim, Jeffrey H. Kozlow, Bharat Mittal, Jeffrey Moyer, Thomas Olencki, Phillip Rodgers, Christopher Bichakjian, April Armstrong, Christian Baum, Jeremy S. Bordeaux, Marc Brown, Klaus J. Busam, Daniel B. Eisen, Vivek Iyengar, Clifford Lober, David J. Margolis, Jane Messina, Alexander Miller, Stanley Miller, Eliot Mostow, Christen Mowad, Kishwer Nehal, Kristi Schmitt-Burr, Aleksandar Sekulic, Paul Storrs, Joyce Teng, Siegrid Yu, Conway Huang, Kevin Boyer, Wendy Smith Begolka, Murad Alam
Publikováno v:
Journal of the American Academy of Dermatology. 78:540-559
Basal cell carcinoma (BCC) is the most common form of human cancer, with a continually increasing annual incidence in the United States. When diagnosed early, the majority of BCCs are readily treated with office-based therapy, which is highly curativ
Autor:
Theodoros N. Teknos, Nolan B. Seim, Thomas Olencki, Michael M. Li, Stephen Y. Kang, Dustin A. Silverman
Publikováno v:
Otolaryngology Case Reports, Vol 20, Iss, Pp 100284-(2021)
Objective(s) Vismodegib, a unique hedgehog pathway inhibitor, has been demonstrated to be effective in the treatment of non-operable and metastatic basal cell carcinoma (BCC). While effective, concerns regarding its role in the development of cutaneo
Autor:
Evan J. Lipson, Ragini R. Kudchadkar, Sunil Reddy, Tomoko Akaike, Thomas Olencki, William H. Sharfman, Philip Friedlander, Steven P. Fling, Mizuho Kalabis, Candice D. Church, Kari Kendra, Michi M. Shinohara, Adil Daud, Adam I. Riker, Harriet M. Kluger, Elad Sharon, Melissa Amber Burgess, Janis M. Taube, Paul Nghiem, Brent A. Hanks, Suzanne L. Topalian, Blanca Homet Moreno, Andrew S. Brohl, Brian C. Boulmay, Martin A. Cheever, Bob Salim, Erin Jensen, Shailender Bhatia, Nirasha Ramchurren
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 4
Journal for Immunotherapy of Cancer
BackgroundMerkel cell carcinoma (MCC) is an aggressive skin cancer associated with poor survival. Programmed cell death-1 (PD-1) pathway inhibitors have shown high rates of durable tumor regression compared with chemotherapy for MCC. The current stud
Autor:
Elizabeth R. Plimack, Guru Sonpavde, Clayton Lau, Jeffrey A. Sosman, Thomas Olencki, Phillip M. Pierorazio, Rashmi Kumar, Thomas H. Gallagher, Won Kim, Ithaar Derweesh, Brian Shuch, Steven L. Hancock, Christos Kyriakopoulos, Chad A. LaGrange, Michael R. Harrison, Neeraj Agarwal, M. Dror Michaelson, Mary A. Dwyer, William P Bro, Toni K. Choueiri, Bruce G. Redman, Robert J. Motzer, John L. Gore, Brad Somer, Brian A. Costello, Eric Jonasch, Sam S. Chang, Sam B. Bhayani, Elaine T. Lam, Mayer Fishman
Publikováno v:
Journal of the National Comprehensive Cancer Network. 15:804-834
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for the clinical management of patients with clear cell and non-clear cell renal carcinoma. These guidelines are developed by a multidisciplinary panel of leading experts
Autor:
Darren R. Feldman, Toni K. Choueiri, Joel Picus, Ben L. Sanford, Olwen Hahn, M. Dror Michaelson, Shaker R. Dakhil, Daniel J. George, Meghara K. Walsh, Thomas Olencki, Eric J. Small, Susan Halabi, Michael J. Morris
Publikováno v:
Journal of Clinical Oncology. 35:591-597
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cab